Loading...

IVVD INVIVYD INC Expansion Plans 8-K Filing

NVVY

VVD

INVIVYD INC

(IVVD)

2025 8-K

Show Summary

Summary

SPEAR Study Group

Product Expansion

Financial Statements

Product Expansion

Failure to Meet Listing Sta...

Director Appointment

Financial Results

Nasdaq Compliance

Q4 2024 Results

PEMGARDA Update

Director Resignation

Financial Results

Q3 2024 Results

Virology Data Release

Corporate Update

Clinical Trial Launch

PEMGARDA Update

COVID-19 Treatment Update

Financial Results

Management Changes

Annual Meeting of Stockholders

Financial Results and Corpo...

Departure of CEO and Appoin...

Financial Results Announcement

Departure of Director, Refi...

Other Special Situation

Sales Agreement

Clinical Trial Results

Financial Results Announcement

Earnings Report

Appointment of Director

Amendment to Certificate of...

Financial Results Announcement

Incentive Program Approval

Financial Results Announcement

Announcement of COVID-19 th...

External Links:

On June 26, 2025, Invivyd, Inc. announced positive Phase 1/2 clinical data for VYD2311, a potential COVID-19 monoclonal antibody treatment. This event highlights the company's advancements in non-vaccine preventative and treatment options.

AI Assistant

INVIVYD INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.